BE2014C055I2 - - Google Patents
Download PDFInfo
- Publication number
- BE2014C055I2 BE2014C055I2 BE2014C055C BE2014C055C BE2014C055I2 BE 2014C055 I2 BE2014C055 I2 BE 2014C055I2 BE 2014C055 C BE2014C055 C BE 2014C055C BE 2014C055 C BE2014C055 C BE 2014C055C BE 2014C055 I2 BE2014C055 I2 BE 2014C055I2
- Authority
- BE
- Belgium
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D215/00—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems
- C07D215/02—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom
- C07D215/16—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D215/20—Oxygen atoms
- C07D215/22—Oxygen atoms attached in position 2 or 4
- C07D215/233—Oxygen atoms attached in position 2 or 4 only one oxygen atom which is attached in position 4
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/47—Quinolines; Isoquinolines
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/47—Quinolines; Isoquinolines
- A61K31/4709—Non-condensed quinolines and containing further heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/47—Quinolines; Isoquinolines
- A61K31/472—Non-condensed isoquinolines, e.g. papaverine
- A61K31/4725—Non-condensed isoquinolines, e.g. papaverine containing further heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/496—Non-condensed piperazines containing further heterocyclic rings, e.g. rifampin, thiothixene
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/50—Pyridazines; Hydrogenated pyridazines
- A61K31/501—Pyridazines; Hydrogenated pyridazines not condensed and containing further heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/506—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim not condensed and containing further heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/517—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with carbocyclic ring systems, e.g. quinazoline, perimidine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
- A61K31/5375—1,4-Oxazines, e.g. morpholine
- A61K31/5377—1,4-Oxazines, e.g. morpholine not condensed and containing further heterocyclic rings, e.g. timolol
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/06—Antipsoriatics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/02—Antineoplastic agents specific for leukemia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/08—Antiallergic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D215/00—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems
- C07D215/02—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom
- C07D215/16—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D215/20—Oxygen atoms
- C07D215/22—Oxygen atoms attached in position 2 or 4
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D215/00—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems
- C07D215/02—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom
- C07D215/16—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D215/36—Sulfur atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D215/00—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems
- C07D215/02—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom
- C07D215/16—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D215/38—Nitrogen atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D215/00—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems
- C07D215/02—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom
- C07D215/16—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D215/38—Nitrogen atoms
- C07D215/42—Nitrogen atoms attached in position 4
- C07D215/46—Nitrogen atoms attached in position 4 with hydrocarbon radicals, substituted by nitrogen atoms, attached to said nitrogen atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D239/00—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings
- C07D239/70—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings condensed with carbocyclic rings or ring systems
- C07D239/72—Quinazolines; Hydrogenated quinazolines
- C07D239/86—Quinazolines; Hydrogenated quinazolines with hetero atoms directly attached in position 4
- C07D239/88—Oxygen atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D239/00—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings
- C07D239/70—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings condensed with carbocyclic rings or ring systems
- C07D239/72—Quinazolines; Hydrogenated quinazolines
- C07D239/86—Quinazolines; Hydrogenated quinazolines with hetero atoms directly attached in position 4
- C07D239/94—Nitrogen atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D295/00—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms
- C07D295/04—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms with substituted hydrocarbon radicals attached to ring nitrogen atoms
- C07D295/14—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms with substituted hydrocarbon radicals attached to ring nitrogen atoms substituted by carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals
- C07D295/145—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms with substituted hydrocarbon radicals attached to ring nitrogen atoms substituted by carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals with the ring nitrogen atoms and the carbon atoms with three bonds to hetero atoms attached to the same carbon chain, which is not interrupted by carbocyclic rings
- C07D295/15—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms with substituted hydrocarbon radicals attached to ring nitrogen atoms substituted by carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals with the ring nitrogen atoms and the carbon atoms with three bonds to hetero atoms attached to the same carbon chain, which is not interrupted by carbocyclic rings to an acyclic saturated chain
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
- C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
- C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
- C07D403/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
- C07D405/14—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
- C07D413/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D413/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
- C07D417/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
- C07D417/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
- C12Q1/48—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving transferase
- C12Q1/485—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving transferase involving kinase
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N2500/00—Screening for compounds of potential therapeutic value
- G01N2500/04—Screening involving studying the effect of compounds C directly on molecule A (e.g. C are potential ligands for a receptor A, or potential substrates for an enzyme A)
-
- Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
- Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
- Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
- Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change
Applications Claiming Priority (4)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US50618103P | 2003-09-26 | 2003-09-26 | |
US53537704P | 2004-01-09 | 2004-01-09 | |
US57738404P | 2004-06-04 | 2004-06-04 | |
EP04789057A EP1673085B1 (en) | 2003-09-26 | 2004-09-24 | C-met modulators and methods of use |
Publications (1)
Publication Number | Publication Date |
---|---|
BE2014C055I2 true BE2014C055I2 (en) | 2023-12-14 |
Family
ID=34397024
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
BE2014C055C BE2014C055I2 (en) | 2003-09-26 | 2014-09-10 |
Country Status (19)
Country | Link |
---|---|
US (14) | US9174947B2 (en) |
EP (9) | EP3329918B1 (en) |
JP (14) | JP4638436B2 (en) |
AT (3) | ATE532782T1 (en) |
AU (3) | AU2004275842B2 (en) |
BE (1) | BE2014C055I2 (en) |
CA (2) | CA2537812C (en) |
CY (3) | CY1111956T1 (en) |
DK (4) | DK2213661T3 (en) |
ES (6) | ES2369652T3 (en) |
HK (5) | HK1141799A1 (en) |
HR (4) | HRP20110707T1 (en) |
HU (1) | HUS1400052I1 (en) |
LU (1) | LU92508I2 (en) |
NL (1) | NL300678I2 (en) |
PL (3) | PL2392565T3 (en) |
PT (2) | PT2213661E (en) |
SI (4) | SI2392564T1 (en) |
WO (1) | WO2005030140A2 (en) |
Families Citing this family (260)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
NZ525324A (en) | 2000-10-20 | 2005-03-24 | Eisai Co Ltd | Nitrogenous aromatic ring compounds |
ATE508747T1 (en) | 2003-03-10 | 2011-05-15 | Eisai R&D Man Co Ltd | C-KIT KINASE INHIBITORS |
ES2279441T3 (en) | 2003-09-19 | 2007-08-16 | Astrazeneca Ab | DERIVATIVES OF QUINAZOLINA. |
CA2537812C (en) * | 2003-09-26 | 2013-01-22 | Exelixis, Inc. | C-met modulators and method of use |
CN101337930B (en) | 2003-11-11 | 2010-09-08 | 卫材R&D管理有限公司 | Urea derivative preparation process |
CA2545711A1 (en) | 2003-11-13 | 2005-06-02 | Ambit Biosciences Corporation | Urea derivatives as kinase modulators |
EP1711495A2 (en) * | 2004-01-23 | 2006-10-18 | Amgen Inc. | Quinoline, quinazoline, pyridine and pyrimidine counds and their use in the treatment of inflammation, angiogenesis and cancer |
CA2543859A1 (en) * | 2004-02-27 | 2005-09-09 | Eisai Co., Ltd. | Novel pyridine derivative and pyrimidine derivative (1) |
CA2567574C (en) | 2004-04-08 | 2013-01-08 | Targegen, Inc. | Benzotriazine inhibitors of kinases |
EP2532653A1 (en) * | 2004-08-25 | 2012-12-12 | Targegen, Inc. | Benzo[1,2,4]triazines as protein kinase modulators |
AU2005283422C1 (en) | 2004-09-17 | 2017-02-02 | Eisai R & D Management Co., Ltd. | Medicinal composition |
AR051202A1 (en) | 2004-09-20 | 2006-12-27 | Xenon Pharmaceuticals Inc | HETEROCICLIC DERIVATIVES AND THEIR USE AS INHIBITORS OF ESTEAROIL-COA DESATURASA |
AR051094A1 (en) | 2004-09-20 | 2006-12-20 | Xenon Pharmaceuticals Inc | HETEROCICLIC DERIVATIVES AND THEIR USE AS INHIBITORS OF ESTEAROIL-COA DESATURASA |
AU2005286846A1 (en) | 2004-09-20 | 2006-03-30 | Xenon Pharmaceuticals Inc. | Heterocyclic derivatives and their use as therapeutic agents |
BRPI0515483A (en) | 2004-09-20 | 2008-07-22 | Xenon Pharmaceuticals Inc | heterocyclic derivatives for the treatment of stearoyl coa desaturase mediated diseases |
TW200626572A (en) | 2004-09-20 | 2006-08-01 | Xenon Pharmaceuticals Inc | Heterocyclic derivatives and their use as therapeutic agents |
BRPI0515505A (en) | 2004-09-20 | 2008-07-29 | Xenon Pharmaceuticals Inc | heterocyclic derivatives and their use as stearoyl coat desaturase inhibitors |
EP1804799B1 (en) | 2004-09-20 | 2013-08-21 | Xenon Pharmaceuticals Inc. | Heterocyclic derivatives and their use as stearoyl-coa desaturase inhibitors |
CA2581516C (en) | 2004-10-12 | 2013-06-11 | Astrazeneca Ab | Quinazoline derivatives |
EP1827434B1 (en) | 2004-11-30 | 2014-01-15 | Amgen Inc. | Quinolines and quinazoline analogs and their use as medicaments for treating cancer |
EP1674466A1 (en) * | 2004-12-27 | 2006-06-28 | 4Sc Ag | 2,5- and 2,6-disubstituted benzazole analogues useful as protein kinase inhibitors |
US7576090B2 (en) * | 2004-12-27 | 2009-08-18 | 4Sc Ag | Benzazole analogues and uses thereof |
JO2787B1 (en) | 2005-04-27 | 2014-03-15 | امجين إنك, | Substituted Amid derivatives & methods of use |
WO2008041053A2 (en) * | 2005-05-20 | 2008-04-10 | Methylgene, Inc. | Inhibitors of vegf receptor and hgf receptor signaling |
US20070036797A1 (en) * | 2005-06-02 | 2007-02-15 | Galaxy Biotech, Llc | Methods of treating brain tumors with antibodies |
EP2540296A1 (en) | 2005-06-03 | 2013-01-02 | Xenon Pharmaceuticals Inc. | Arminothiazole derivatives as human stearoyl-coa desaturase inhibitors |
EP2281901B1 (en) | 2005-08-02 | 2013-11-27 | Eisai R&D Management Co., Ltd. | Anti-tumour pharmaceutical composition with angiogenesis inhibitors |
CA2605854C (en) | 2005-08-24 | 2010-08-17 | Eisai R & D Management Co., Ltd. | Novel pyridine derivative and pyrimidine derivative (3) |
TWI387592B (en) | 2005-08-30 | 2013-03-01 | Novartis Ag | Substituted benzimidazoles and methods of their use as inhibitors of kinases associated with tumorigenesis |
WO2007033196A1 (en) | 2005-09-14 | 2007-03-22 | Bristol-Myers Squibb Company | Met kinase inhibitors |
WO2007061127A1 (en) * | 2005-11-22 | 2007-05-31 | Eisai R & D Management Co., Ltd. | Anti-tumor agent for multiple myeloma |
WO2008063202A2 (en) * | 2006-01-30 | 2008-05-29 | Array Biopharma Inc. | Heterobicyclic thiophene compounds for the treatment of cancer |
UY30183A1 (en) | 2006-03-02 | 2007-10-31 | Astrazeneca Ab | QUINOLINE DERIVATIVES |
CA2645137A1 (en) | 2006-03-07 | 2007-09-13 | James F. Blake | Heterobicyclic pyrazole compounds and methods of use |
AR059922A1 (en) * | 2006-04-01 | 2008-05-07 | Galaxy Biotech Llc | HUMANIZED MONOCLONAL ANTIBODIES FOR THE GROWTH FACTOR OF HEPATOCITS |
HUE035654T2 (en) * | 2006-04-19 | 2018-05-28 | Novartis Ag | 6-o-substituted benzoxazole and benzothiazole compounds and methods of inhibiting csf-1r signaling |
US20090209580A1 (en) | 2006-05-18 | 2009-08-20 | Eisai R & D Management Co., Ltd. | Antitumor agent for thyroid cancer |
NZ573735A (en) | 2006-05-19 | 2011-10-28 | Abbott Lab | Cns active fused bicycloheterocycle substituted azabicyclic alkane derivatives |
WO2008035209A2 (en) * | 2006-05-30 | 2008-03-27 | Methylgene Inc. | Inhibitors of protein tyrosine kinase activity |
JP2009539878A (en) * | 2006-06-08 | 2009-11-19 | アレイ バイオファーマ、インコーポレイテッド | Quinoline compounds and methods of use |
CA2660836A1 (en) | 2006-08-07 | 2008-02-21 | Incyte Corporation | Triazolotriazines as kinase inhibitors |
CN101454311B (en) * | 2006-08-23 | 2013-03-27 | 卫材R&D管理有限公司 | Salt of phenoxypyridine derivative or crystal thereof and process for producing the same |
EP2065372B1 (en) | 2006-08-28 | 2012-11-28 | Eisai R&D Management Co., Ltd. | Antitumor agent for undifferentiated gastric cancer |
US7790885B2 (en) | 2006-08-31 | 2010-09-07 | Eisai R&D Management Co., Ltd. | Process for preparing phenoxypyridine derivatives |
TWI432427B (en) | 2006-10-23 | 2014-04-01 | Cephalon Inc | Fused bicyclic derivatives of 2,4-diaminopyrimidine as alk and c-met inhibitors |
EP2079738A2 (en) * | 2006-10-27 | 2009-07-22 | Glaxo Group Limited | 7-azaindole derivatives as c-met kinase inhibitors |
MY188335A (en) | 2006-11-22 | 2021-11-30 | Incyte Holdings Corp | Imidazotriazines and imidazopyrimidines as kinase inhibitors |
US7915287B2 (en) * | 2006-12-20 | 2011-03-29 | Amgen Inc. | Substituted heterocycles and methods of use |
WO2008079291A2 (en) * | 2006-12-20 | 2008-07-03 | Amgen Inc. | Substituted heterocycles and methods of use |
ES2531002T3 (en) * | 2007-01-19 | 2015-03-09 | Xcovery Inc | Kinase Inhibitor Compounds |
KR101445892B1 (en) | 2007-01-29 | 2014-09-29 | 에자이 알앤드디 매니지먼트 가부시키가이샤 | Composition for treatment of undifferentiated-type of gastric cancer |
JP5378362B2 (en) * | 2007-05-21 | 2013-12-25 | ノバルティス アーゲー | CSF-1R inhibitors, compositions and methods of use |
DE102007026341A1 (en) | 2007-06-06 | 2008-12-11 | Merck Patent Gmbh | Benzoxazolonderivate |
WO2009021965A2 (en) | 2007-08-15 | 2009-02-19 | Glaxo Group Limited | Substituted quinoline derivatives as h1 receptor antagonists |
EP2183254B1 (en) | 2007-08-29 | 2017-06-21 | MethylGene Inc. | Inhibitors of protein tyrosine kinase activity |
JP5638244B2 (en) | 2007-11-09 | 2014-12-10 | エーザイ・アール・アンド・ディー・マネジメント株式会社 | Combination of angiogenesis inhibitors and antitumor platinum complexes |
JP2009132660A (en) | 2007-11-30 | 2009-06-18 | Eisai R & D Management Co Ltd | Composition for treating esophageal cancer |
US8558000B2 (en) | 2008-01-23 | 2013-10-15 | Bristol-Myers Squibb Company | 4-pyridinone compounds and their use for cancer |
EP3147281A1 (en) | 2008-03-17 | 2017-03-29 | Ambit Biosciences Corporation | Quinazoline derivatives as raf kinase modulators and methods of use thereof |
KR101414931B1 (en) | 2008-04-10 | 2014-07-04 | 다이호야쿠힌고교 가부시키가이샤 | Acylthiourea compound or salt thereof, and use of the compound or the salt |
RU2010146474A (en) * | 2008-04-16 | 2012-05-27 | Макс-Планк-Гезелльшафт Цур Фердерунг Дер Виссеншафтен Е.Ф. (De) | QUINOLINE DERIVATIVES AS AXL KINAZ INHIBITORS |
UY31800A (en) * | 2008-05-05 | 2009-11-10 | Smithkline Beckman Corp | CANCER TREATMENT METHOD USING A CMET AND AXL INHIBITOR AND AN ERBB INHIBITOR |
ES2643363T3 (en) | 2008-05-21 | 2017-11-22 | Incyte Holdings Corporation | Salts of 2-fluoro-N-methyl-4- [7- (quinolin-6-yl-methyl) -imidazo [1,2-b] [1,2,4] triazin-2-yl] benzamide and related processes with the preparation of them |
US8124764B2 (en) | 2008-07-14 | 2012-02-28 | Gilead Sciences, Inc. | Fused heterocyclyc inhibitor compounds |
JP5640005B2 (en) | 2008-07-14 | 2014-12-10 | ギリアード サイエンシーズ, インコーポレイテッド | Imidazosylpyridine compounds as HDAC and / or CDK inhibitors |
WO2010009166A1 (en) | 2008-07-14 | 2010-01-21 | Gilead Colorado, Inc. | Oxindolyl inhibitor compounds |
EP2149565A1 (en) * | 2008-07-24 | 2010-02-03 | Bayer Schering Pharma AG | Sulfoximine substituted chinazoline derivatives as immune modulators for the treatment of inflammatory and allergic diseases |
NZ590747A (en) | 2008-07-28 | 2012-11-30 | Gilead Sciences Inc | Cycloalkylidene and heterocycloalkylidene hdac inhibitor compounds |
AR075084A1 (en) * | 2008-09-26 | 2011-03-09 | Smithkline Beecham Corp | PREPARATION METHOD OF QUINOLINIL -OXIDIFENIL - CYCLOPROPANODICARBOXAMIDS AND CORRESPONDING INTERMEDIARIES |
AU2009303602B2 (en) * | 2008-10-14 | 2012-06-14 | Sunshine Lake Pharma Co., Ltd. | Compounds and methods of use |
US8278331B2 (en) * | 2008-10-29 | 2012-10-02 | Deciphera Pharmaceuticals, Llc | N-acyl ureas exhibiting anti-cancer and anti-proliferative activities |
KR20110084455A (en) * | 2008-11-13 | 2011-07-22 | 엑셀리시스, 인코포레이티드 | Methods of preparing quinoline derivatives |
CN102239148A (en) * | 2008-12-04 | 2011-11-09 | 埃克塞里艾克西斯公司 | Methods of preparing quinoline derivatives |
DE102009003975A1 (en) | 2009-01-07 | 2010-07-08 | Merck Patent Gmbh | Benzothiazolonderivate |
EA019959B1 (en) * | 2009-01-16 | 2014-07-30 | Экселиксис, Инк. | Malate salt of n-(4-{[6,7-bis(methyloxy)quin0lin-4-yl]oxy}phenyl)-n'-(4-fluorophenyl)cyclopropane-1,1-dicarboxamide, and crystalline forms thereof for the treatment of cancer |
EP2210891A1 (en) * | 2009-01-26 | 2010-07-28 | Domain Therapeutics | New adenosine receptor ligands and uses thereof |
WO2010111063A1 (en) * | 2009-03-21 | 2010-09-30 | Ning Xi | Amino ester derivatives, salts thereof and methods of use |
KR20120061063A (en) | 2009-06-05 | 2012-06-12 | 화이자 인코포레이티드 | L-(piperidin-4-yl)-pyrazole derivatives as gpr119 modulators |
KR20120024722A (en) | 2009-06-08 | 2012-03-14 | 길리애드 사이언시즈, 인코포레이티드 | Cycloalkylcarbamate benzamide aniline hdac inhibitor compounds |
JP5586692B2 (en) | 2009-06-08 | 2014-09-10 | ギリアード サイエンシーズ, インコーポレイテッド | Alkanoylaminobenzamidoaniline HDAC inhibitor compound |
NZ597695A (en) * | 2009-07-17 | 2014-05-30 | Exelixis Inc | Crystalline forms of n-[3-fluoro-4-({ 6-(methyloxy)-7-[(3-morpholin-4-ylpropyl)oxy]-quinolin-4-yl} oxy)phenyl]-n’-(4-fluorophenyl)cyclopropane-1, 1-dicarboxamide |
UA108618C2 (en) * | 2009-08-07 | 2015-05-25 | APPLICATION OF C-MET-MODULATORS IN COMBINATION WITH THEMOSOLOMID AND / OR RADIATION THERAPY FOR CANCER TREATMENT | |
CN102030705B (en) * | 2009-09-30 | 2012-12-19 | 上海睿智化学研究有限公司 | Synthesis method of 7- benzyloxy-6-methoxyl-4-hydroxyquinoline |
EP2311809A1 (en) * | 2009-10-16 | 2011-04-20 | Max-Planck-Gesellschaft zur Förderung der Wissenschaften e.V. | Quinolinyloxyphenylsulfonamides |
EA021439B1 (en) * | 2009-11-03 | 2015-06-30 | ГЛЭКСОСМИТКЛАЙН ЭлЭлСи | Quinazoline compounds |
EP2521548A2 (en) * | 2009-11-27 | 2012-11-14 | Proteologics, Ltd | Quinazolin-4(3a)-one derivatives and methods of use thereof |
DE102009056886A1 (en) | 2009-12-03 | 2011-06-09 | Bayer Schering Pharma Aktiengesellschaft | cMet inhibitors for the treatment of endometriosis |
CN102086211B (en) * | 2009-12-08 | 2013-09-11 | 广东东阳光药业有限公司 | Aromatic heterocyclic compounds serving as protein kinase inhibitor |
JP5714030B2 (en) | 2010-02-03 | 2015-05-07 | インサイト コーポレーションIncyte Corporation | Imidazo [1,2-b] [1,2,4] triazines as C-Met inhibitors |
US20130143881A1 (en) * | 2010-03-12 | 2013-06-06 | Exelixis, Inc. | Hydrated Crystalline Forms of N-[3-fluoro-4-(oxy)phenyl]-N'-(4-fluorophenyl)cyclopropane-1,1-dicarboxamide |
EP2553641A4 (en) * | 2010-03-26 | 2015-01-07 | EastNets | Mobile remittance computer system and method |
CN102212062B (en) * | 2010-04-02 | 2015-04-29 | 广东东阳光药业有限公司 | Derivative of amino ester, salt thereof and using method |
US20120070368A1 (en) * | 2010-04-16 | 2012-03-22 | Exelixis, Inc. | Methods of Using C-Met Modulators |
AR081331A1 (en) | 2010-04-23 | 2012-08-08 | Cytokinetics Inc | AMINO- PYRIMIDINES COMPOSITIONS OF THE SAME AND METHODS FOR THE USE OF THE SAME |
EP2560488B1 (en) | 2010-04-23 | 2015-10-28 | Cytokinetics, Inc. | Certain amino-pyridines and amino-triazines, compositions thereof, and methods for their use |
AR081626A1 (en) | 2010-04-23 | 2012-10-10 | Cytokinetics Inc | AMINO-PYRIDAZINIC COMPOUNDS, PHARMACEUTICAL COMPOSITIONS THAT CONTAIN THEM AND USE OF THE SAME TO TREAT CARDIAC AND SKELETIC MUSCULAR DISORDERS |
US8569319B2 (en) | 2010-04-29 | 2013-10-29 | Deciphera Pharmaceuticals, LLS | Pyridone amides and analogs exhibiting anti-cancer and anti-proliferative activities |
EP2571878B1 (en) | 2010-05-17 | 2018-10-17 | Incozen Therapeutics Pvt. Ltd. | Novel 3,5-disubstitued-3h-imidazo[4,5-b]pyridine and 3,5- disubstitued -3h-[1,2,3]triazolo[4,5-b]pyridine compounds as modulators of protein kinases |
US9012458B2 (en) | 2010-06-25 | 2015-04-21 | Eisai R&D Management Co., Ltd. | Antitumor agent using compounds having kinase inhibitory effect in combination |
EP2588107A1 (en) | 2010-07-01 | 2013-05-08 | Takeda Pharmaceutical Company Limited | COMBINATION OF A cMET INHIBITOR AND AN ANTIBODY TO HGF AND/OR cMET |
AR082252A1 (en) * | 2010-07-16 | 2012-11-21 | Exelixis Inc | C-MET MODULATING PHARMACEUTICAL COMPOSITIONS |
US20140186407A9 (en) | 2010-07-16 | 2014-07-03 | Exelixis Inc. | C-Met Modulator Pharmaceutical Compositions |
EP2423208A1 (en) | 2010-08-28 | 2012-02-29 | Lead Discovery Center GmbH | Pharmaceutically active compounds as Axl inhibitors |
US8664244B2 (en) * | 2010-09-12 | 2014-03-04 | Advenchen Pharmaceuticals, LLC | Compounds as c-Met kinase inhibitors |
US20140057908A1 (en) | 2010-09-27 | 2014-02-27 | Exelixis, Inc. | Method of Treating Cancer |
JP6158705B2 (en) * | 2010-09-27 | 2017-07-05 | エクセリクシス, インク. | Dual inhibitors of MET and VEGF for the treatment of castration resistant prostate cancer and osteogenic metastases |
CA2812753A1 (en) * | 2010-09-27 | 2012-04-05 | Exelixis, Inc. | Dual inhibitors of met and vegf for the treatment of castration resistant prostate cancer and osteoblastic bone metastases |
WO2012042421A1 (en) | 2010-09-29 | 2012-04-05 | Pfizer Inc. | Method of treating abnormal cell growth |
US20130252956A1 (en) * | 2010-11-22 | 2013-09-26 | Howard Kallender | Methods of treating cancer |
CN102093421B (en) | 2011-01-28 | 2014-07-02 | 北京康辰药业有限公司 | Phosphorus substituent group-containing quinoline compound and preparation method of quinoline compound as well as pharmaceutical composition containing quinoline compound and application of pharmaceutical composition |
KR20210010671A (en) * | 2011-02-10 | 2021-01-27 | 엑셀리시스, 인코포레이티드 | Processes for preparing quinoline compounds and pharmaceutical compositions containing such compounds |
BR112013022307A2 (en) | 2011-03-04 | 2020-09-24 | Glaxosmithkline Intellectual Property (No. 2) Limited | aminoquinolines as kinase inhibitors |
US20120252840A1 (en) * | 2011-04-04 | 2012-10-04 | Exelixis, Inc. | Method of Treating Cancer |
US8962650B2 (en) | 2011-04-18 | 2015-02-24 | Eisai R&D Management Co., Ltd. | Therapeutic agent for tumor |
US8759380B2 (en) | 2011-04-22 | 2014-06-24 | Cytokinetics, Inc. | Certain heterocycles, compositions thereof, and methods for their use |
TWI610918B (en) * | 2011-05-02 | 2018-01-11 | 艾克塞里克斯公司 | Method of treating cancer and bone cancer pain |
US9945862B2 (en) | 2011-06-03 | 2018-04-17 | Eisai R&D Management Co., Ltd. | Biomarkers for predicting and assessing responsiveness of thyroid and kidney cancer subjects to lenvatinib compounds |
TWI547494B (en) | 2011-08-18 | 2016-09-01 | 葛蘭素史克智慧財產發展有限公司 | Amino quinazolines as kinase inhibitors |
EP2753176A4 (en) * | 2011-09-06 | 2015-10-21 | New York Blood Ct Inc | Hiv inhibitors |
CN102408411B (en) | 2011-09-19 | 2014-10-22 | 北京康辰药业股份有限公司 | Hydroximic acid compound containing quinolyl and preparation method thereof, and drug composition containing the compound and use thereof |
AU2012312364B2 (en) * | 2011-09-22 | 2017-11-09 | Exelixis, Inc. | Method for treating osteoporosis |
PT2768796T (en) * | 2011-10-20 | 2020-02-21 | Exelixis Inc | Process for preparing quinoline derivatives |
US8843421B2 (en) | 2011-11-01 | 2014-09-23 | Accenture Global Services Limited | Identification of entities likely to engage in a behavior |
EA201490946A1 (en) | 2011-11-08 | 2014-08-29 | Экселиксис, Инк. | METHOD OF QUANTITATIVE EVALUATION OF CANCER TREATMENT |
EP2776033A1 (en) | 2011-11-08 | 2014-09-17 | Exelixis, Inc. | Dual inhibitor of met and vegf for treating cancer |
TWI577671B (en) | 2011-11-14 | 2017-04-11 | Sunshine Lake Pharma Co Ltd | Aminoquinazoline derivatives and salts thereof and methods of use thereof |
EP2796451B1 (en) * | 2011-12-20 | 2018-08-01 | Wei Qian | Heterocycle amido alkyloxy substituted quinazoline derivative and use thereof |
CN102643268B (en) * | 2011-12-30 | 2014-05-21 | 沈阳药科大学 | Quinoline and cinnoline compound and application thereof |
EP2620869B1 (en) | 2012-01-27 | 2017-11-01 | Optim Corporation | Portable terminal, method, and program of changing user interface |
US9358235B2 (en) * | 2012-03-19 | 2016-06-07 | Plexxikon Inc. | Kinase modulation, and indications therefor |
AP3908A (en) | 2012-03-30 | 2016-11-24 | Rhizen Pharmaceuticals Sa | Novel 3,5-disubstituted-3H-imidazo[4,5-B]pyridine and 3,5-disubstituted-3H-[1,2,3]triazolo [4,5-B] pyridine compounds as modulators of C-met protein kinases |
WO2013152252A1 (en) | 2012-04-06 | 2013-10-10 | OSI Pharmaceuticals, LLC | Combination anti-cancer therapy |
US9861624B2 (en) | 2012-05-02 | 2018-01-09 | Exelixis, Inc. | Method of treating cancer |
WO2013180128A1 (en) * | 2012-05-28 | 2013-12-05 | 協和発酵キリン株式会社 | 4-[4-(5-membered aromatic heterocyclic carbonyl ureide)phenyloxy]quinoline derivative |
CN103509024B (en) * | 2012-06-28 | 2015-10-28 | 上海医药工业研究院 | Kui Linpyrimido quinoline benzazepine compounds and the application as antitumor drug thereof |
CN103626762B (en) * | 2012-08-24 | 2015-07-29 | 上海医药工业研究院 | Benazepine compound and application thereof |
CN103626761B (en) * | 2012-08-24 | 2015-07-29 | 上海医药工业研究院 | Benazepine compound and the application as antitumor drug thereof |
AR092529A1 (en) | 2012-09-13 | 2015-04-22 | Glaxosmithkline Llc | AMINOQUINAZOLINE COMPOUND, PHARMACEUTICAL COMPOSITION THAT INCLUDES IT AND USE OF THIS COMPOSITE FOR THE PREPARATION OF A MEDICINAL PRODUCT |
AR092530A1 (en) | 2012-09-13 | 2015-04-22 | Glaxosmithkline Llc | AMINO-QUINOLINE COMPOSITE, PHARMACEUTICAL COMPOSITION THAT INCLUDES IT AND USE OF THIS COMPOUND FOR THE PREPARATION OF A MEDICINAL PRODUCT |
CN103664776B (en) * | 2012-09-26 | 2016-05-04 | 正大天晴药业集团股份有限公司 | The preparation method of a kind of tyrosine kinase inhibitor and intermediate thereof |
CN103705521A (en) * | 2012-09-28 | 2014-04-09 | 韩冰 | Compound for treating cerebral infarction and application thereof |
CN103804382A (en) * | 2012-11-05 | 2014-05-21 | 韩文毅 | Compound for treating eczema and application thereof |
CN103804305A (en) * | 2012-11-05 | 2014-05-21 | 韩文毅 | Compound for treating eczema and application thereof |
CN102977014B (en) * | 2012-11-05 | 2015-01-07 | 沈阳药科大学 | New quinoline compounds and uses thereof |
CN103804381A (en) * | 2012-11-06 | 2014-05-21 | 韩冰 | Compound for treatment of ischemic brain damage and application thereof |
CN103804291A (en) * | 2012-11-07 | 2014-05-21 | 韩冰 | Compound for treating neurodegenerative diseases and application thereof |
CN103800328A (en) * | 2012-11-07 | 2014-05-21 | 韩冰 | Compound for treating neurodegenerative diseases and application thereof |
CN103804290A (en) * | 2012-11-07 | 2014-05-21 | 韩冰 | Compound for treating neurodegenerative diseases and application thereof |
CN103804361A (en) * | 2012-11-07 | 2014-05-21 | 韩冰 | Compound for treating neurodegenerative diseases and application thereof |
CN103800340A (en) * | 2012-11-09 | 2014-05-21 | 韩冰 | Compounds for treating glaucoma and application thereof |
CN103804298A (en) * | 2012-11-09 | 2014-05-21 | 韩冰 | Compounds for treating glaucoma and application thereof |
CN103804306A (en) * | 2012-11-12 | 2014-05-21 | 韩文毅 | Compounds for treating diabetes and application thereof |
CN103804362A (en) * | 2012-11-12 | 2014-05-21 | 韩文毅 | Compounds for treating diabetes and application thereof |
CN103804363A (en) * | 2012-11-14 | 2014-05-21 | 韩冰 | Compound with neuroprotective effect and use thereof |
CN102964308B (en) * | 2012-11-30 | 2015-03-18 | 中国药科大学 | Novel pyrimidine compound, preparation method thereof, pharmaceutical composition containing novel pyrimidine compound and application of novel pyrimidine compound |
JPWO2014098176A1 (en) | 2012-12-21 | 2017-01-12 | エーザイ・アール・アンド・ディー・マネジメント株式会社 | Amorphous quinoline derivative and method for producing the same |
CN103965104B (en) * | 2013-01-29 | 2017-09-29 | 正大天晴药业集团股份有限公司 | A kind of preparation method of tyrosine kinase inhibitor and its intermediate |
KR20150118152A (en) | 2013-02-21 | 2015-10-21 | 글락소스미스클라인 인털렉츄얼 프로퍼티 디벨로프먼트 리미티드 | Quinazolines as kinase inhibitors |
WO2014145693A1 (en) * | 2013-03-15 | 2014-09-18 | Exelixis, Inc. | Metabolites of n-[3-fluoro-4-({ 6-(methyloxy)-7-[(3-morpholin-4-ylpropyl)oxy]quinolin-4-yl}oxy)phenyl]-n'-(4-fluorophenyl)cyclopropane-1,1-dicarboxamide |
MX2015011180A (en) * | 2013-03-15 | 2015-11-11 | Hoffmann La Roche | ARYL SULFAMIDE AND SULFAMATE DERIVATIVES AS RORc MODULATORS. |
BR112015023109A2 (en) * | 2013-03-15 | 2018-05-15 | Exelixis Inc | METABOLITES OF N- (4 - {[6,7-BIS (METHYLOXY) QUINOLOIN-4-IL] OXY} PHENYL) -N - (4-FLUOROFENYL) CYCLOPROPANE-1, 1-DICARBOXAMIDE |
CN108472242A (en) * | 2013-04-04 | 2018-08-31 | 埃克塞里艾克西斯公司 | The pharmaceutical composition for the treatment of cancer |
US11564915B2 (en) | 2013-04-04 | 2023-01-31 | Exelixis, Inc. | Cabozantinib dosage form and use in the treatment of cancer |
CN104109128B (en) * | 2013-04-19 | 2016-10-05 | 连云港润众制药有限公司 | Card is rich for Buddhist nun's malate and preparation method thereof |
CN104109124B (en) * | 2013-04-19 | 2016-08-31 | 正大天晴药业集团股份有限公司 | The rich crystal for Buddhist nun 0.5 malate of card |
US10517861B2 (en) | 2013-05-14 | 2019-12-31 | Eisai R&D Management Co., Ltd. | Biomarkers for predicting and assessing responsiveness of endometrial cancer subjects to lenvatinib compounds |
CN104370811B (en) * | 2013-08-15 | 2019-02-12 | 广东东阳光药业有限公司 | A kind of novel crystal forms of quinoline compound and preparation method thereof |
WO2015031604A1 (en) | 2013-08-28 | 2015-03-05 | Crown Bioscience, Inc. | Gene expression signatures predictive of subject response to a multi-kinase inhibitor and methods of using the same |
CN104628657A (en) * | 2013-11-06 | 2015-05-20 | 韩冰 | Class of compounds for treating ischemic brain damage and purpose thereof |
MX2016010266A (en) | 2014-02-14 | 2017-02-08 | Exelixis Inc | Crystalline solid forms of n-{4-[(6,7-dimethoxyquinolin-4-yl)oxy] phenyl}-n'-(4-fluorophenyl) cyclopropane-1, 1-dicarboxamide, processes for making, and methods of use. |
US10231965B2 (en) | 2014-02-20 | 2019-03-19 | Ignyta, Inc. | Molecules for administration to ROS1 mutant cancer cells |
US11040937B2 (en) | 2014-02-28 | 2021-06-22 | Tohoku University | Amide derivative |
CN106255499A (en) | 2014-03-17 | 2016-12-21 | 埃克塞里艾克西斯公司 | The rich administration for Buddhist nun's preparation of card |
BR112016021383A2 (en) | 2014-03-24 | 2017-10-03 | Genentech Inc | METHOD TO IDENTIFY A PATIENT WITH CANCER WHO IS LIKE OR LESS LIKELY TO RESPOND TO TREATMENT WITH A CMET ANTAGONIST, METHOD TO IDENTIFY A PATIENT WITH PREVIOUSLY TREATED CANCER, METHOD TO DETERMINE THE EXPRESSION OF THE HGF BIOMARKER, ANTI-C-MET ANTAGONIST AND ITS USE, DIAGNOSTIC KIT AND ITS PREPARATION METHOD |
CA2946416C (en) | 2014-04-25 | 2022-07-19 | Exelixis, Inc. | Method of treating lung adenocarcinoma |
US9815789B2 (en) | 2014-05-23 | 2017-11-14 | Mylan Laboratories, Ltd. | Polymorphs of cabozantinib (S)-malate and cabozantinib free base |
CN104788372B (en) * | 2014-07-25 | 2018-01-30 | 上海圣考医药科技有限公司 | A kind of deuterated card is rich to replace Buddhist nun's derivative, its preparation method, application and its intermediate |
US11124481B2 (en) * | 2014-07-31 | 2021-09-21 | Exelixis, Inc. | Method of preparing fluorine-18 labeled Cabozantinib and its analogs |
CN106573042A (en) | 2014-08-05 | 2017-04-19 | 埃克塞里艾克西斯公司 | Drug combinations to treat multiple myeloma |
KR102329681B1 (en) | 2014-08-28 | 2021-11-23 | 에자이 알앤드디 매니지먼트 가부시키가이샤 | High-purity quinoline derivative and method for manufacturing same |
US10137107B2 (en) | 2014-09-19 | 2018-11-27 | New York Blood Center, Inc. | Substituted phenylpyrrolecarboxamides with therapeutic activity in HIV |
CN107207471B (en) | 2014-12-02 | 2020-06-26 | 伊尼塔公司 | Combination for the treatment of neuroblastoma |
EP3229836B1 (en) | 2014-12-09 | 2019-11-13 | Institut National de la Sante et de la Recherche Medicale (INSERM) | Human monoclonal antibodies against axl |
DK3263106T3 (en) | 2015-02-25 | 2024-01-08 | Eisai R&D Man Co Ltd | PROCESS FOR SUPPRESSING BITTERNESS OF QUINOLINE DERIVATIVES |
WO2016135041A1 (en) | 2015-02-26 | 2016-09-01 | INSERM (Institut National de la Santé et de la Recherche Médicale) | Fusion proteins and antibodies comprising thereof for promoting apoptosis |
WO2016140717A1 (en) | 2015-03-04 | 2016-09-09 | Merck Sharp & Dohme Corp. | Combination of a pd-1 antagonist and a vegfr/fgfr/ret tyrosine kinase inhibitor for treating cancer |
WO2016150966A1 (en) | 2015-03-25 | 2016-09-29 | Sandoz Ag | Crystalline forms of cabozantinib phosphate and cabozantinib hydrochloride |
CN106279147A (en) * | 2015-05-21 | 2017-01-04 | 中国科学院上海药物研究所 | A kind of pyrido nitrogen heterocyclic and its production and use |
JP6757959B2 (en) | 2015-06-16 | 2020-09-23 | 株式会社 PRISM BioLab | Anti-cancer agent |
US20170020856A1 (en) * | 2015-06-29 | 2017-01-26 | Ontogenesis, Llc | N-Acylalkyl Prodrugs of Multi-Tyrosine Kinase Inhibitors and Methods of Use |
EP3337786B1 (en) | 2015-08-19 | 2019-12-11 | Sandoz AG | Asymmetric bisamidation of malonic ester derivatives |
CN105218445B (en) * | 2015-08-25 | 2018-05-22 | 江苏中邦制药有限公司 | A kind of preparation method of tyrosine kinase inhibitor Foretinib |
CN106543143B (en) * | 2015-09-22 | 2019-03-22 | 合肥中科普瑞昇生物医药科技有限公司 | A kind of novel FLT3 kinase inhibitor and application thereof |
BR112018012255A2 (en) | 2015-12-18 | 2018-12-04 | Ignyta Inc | method to treat cancer |
CN105541798B (en) * | 2016-02-03 | 2018-01-23 | 中国人民解放军第二军医大学 | Quinolines Mutiple Targets kinase inhibitor with antitumor activity and preparation method thereof |
CN107129465B (en) * | 2016-02-26 | 2020-06-19 | 中国科学院上海药物研究所 | Aryl guanidine compound and preparation method and application thereof |
AU2017244139A1 (en) * | 2016-03-31 | 2018-09-13 | Merck Patent Gmbh | Compounds for the inhibition of cyclophilins and uses thereof |
CN109069499A (en) | 2016-04-15 | 2018-12-21 | 埃克塞里艾克西斯公司 | Use N- (4- (6,7- dimethoxy-quinoline -4- base oxygroup) phenyl)-N '-(4- fluorophenyl) cyclopropane -1,1- diformamide, the method for (2S)-hydroxysuccinic acid salts for treating clear-cell carcinoma |
CN105906568A (en) * | 2016-04-28 | 2016-08-31 | 西安交通大学 | Cyclopropane diamide compound with antitumor activity and preparation method and application thereof |
CN106083715A (en) * | 2016-06-01 | 2016-11-09 | 谢阳 | A kind of quinoline, quinazoline compounds and pharmaceutical composition thereof and application |
CN106008371A (en) * | 2016-06-24 | 2016-10-12 | 谢阳 | 1-aryl ureido naphthenic base-1-formamide compound and pharmaceutical composition and application thereof |
CN107556238A (en) * | 2016-06-30 | 2018-01-09 | 深圳万乐药业有限公司 | It is a kind of to block the rich synthetic method for Buddhist nun |
US9957233B1 (en) | 2016-08-05 | 2018-05-01 | Calitor Sciences, Llc | Process for preparing substituted quinolin-4-ol compounds |
WO2018049329A1 (en) * | 2016-09-12 | 2018-03-15 | Zhuhai Beihai Biotech Co., Ltd. | Formulations of cabozantinib |
CN110437145A (en) * | 2016-09-13 | 2019-11-12 | 上海翔锦生物科技有限公司 | Tyrosine kinase inhibitor and its application |
AU2017336547A1 (en) | 2016-09-27 | 2019-05-02 | The United States Of America, As Represented By The Secretary, Department Of Health & Human Services | Method of treating urothelial carcinoma and other genitourinary malignancies using N-(4-(6,7-dimethoxyquinolin-4-yloxy)phenyl)-N'-(4-fluorophenyl)cyclopropane-1,1-dicarboxamide |
AU2017346104B2 (en) * | 2016-10-18 | 2020-06-11 | Beijing Konruns Pharmaceutical Co., Ltd. | Quinolinyl-substituted carboxylic acid compound or pharmaceutically acceptable salt thereof, pharmaceutical composition thereof, and use thereof |
US10799503B2 (en) | 2016-12-01 | 2020-10-13 | Ignyta, Inc. | Methods for the treatment of cancer |
CN106632028B (en) * | 2016-12-22 | 2019-01-22 | 上海再启生物技术有限公司 | A kind of rich preparation method for Buddhist nun of card |
CN108329298A (en) * | 2017-01-17 | 2018-07-27 | 南昌弘益药业有限公司 | A kind of quinolines noval chemical compound preparation method |
BR112019015011A2 (en) | 2017-01-20 | 2020-04-28 | Exelixis Inc | combinations of cabozantinib and atezolizumab to treat cancer |
CA3053739C (en) | 2017-02-15 | 2023-02-14 | Taiho Pharmaceutical Co., Ltd. | Pharmaceutical composition |
CN108503650B (en) * | 2017-02-27 | 2021-02-12 | 北京赛特明强医药科技有限公司 | Dioxane and quinazoline compound or medicinal salt or hydrate thereof and application of dioxane and quinazoline compound or medicinal salt or hydrate thereof as tyrosine kinase inhibitor |
CN110546147B (en) * | 2017-04-27 | 2023-05-23 | 阿斯利康(瑞典)有限公司 | Phenoxyquinazoline compounds and their use in the treatment of cancer |
EA039654B1 (en) | 2017-05-26 | 2022-02-22 | Экселиксис, Инк. | Crystalline solid forms of salts of n-{4-[(6,7-dimethoxyquinolin-4-yl)oxy]phenyl}-n'-(4-fluorphenyl)cyclopropane-1,1-dicarboxamide, processes for making and methods of use |
BR112019025110A2 (en) | 2017-06-09 | 2020-09-01 | Exelixis, Inc. | liquid dosage forms to treat cancer |
CA3069524A1 (en) * | 2017-07-14 | 2019-01-17 | Innate Tumor Immunity, Inc. | Nlrp3 modulators |
WO2019018570A1 (en) | 2017-07-19 | 2019-01-24 | Ignyta, Inc. | Pharmaceutical compositions comprising entrectinib |
US10180422B1 (en) | 2017-08-22 | 2019-01-15 | Scripps Health | Methods of treating a neuroendocrine tumor |
CR20200140A (en) * | 2017-08-31 | 2020-05-15 | Abbvie Inc | Ectonucleotide pyrophosphatase-phosphodiesterase 1 (enpp-1) inhibitors and uses thereof |
CN111225662B (en) | 2017-10-17 | 2022-11-22 | 伊尼塔公司 | Pharmaceutical compositions and dosage forms |
KR20200074164A (en) * | 2017-10-20 | 2020-06-24 | 반더빌트유니버시티 | Antagonist of muscarinic acetylcholine receptor M4 |
JP2021503443A (en) | 2017-10-31 | 2021-02-12 | ヴァンダービルト ユニバーシティー | Antagonist of muscarinic acetylcholine receptor M4 |
CN109824587A (en) * | 2017-11-23 | 2019-05-31 | 上海翔锦生物科技有限公司 | The preparation method of tyrosine kinase inhibitor XJF007 and its intermediate |
CN109896997A (en) * | 2017-12-08 | 2019-06-18 | 中国药科大学 | The preparation method and its usage of N- anilid class c-Met kinase inhibitor |
CA3086522A1 (en) | 2017-12-20 | 2019-06-27 | Angex Pharmaceutical, Inc. | Carbamate and urea compounds as multikinase inhibitors |
US20190262330A1 (en) * | 2017-12-21 | 2019-08-29 | Exelixis, Inc. | Method of Treating Hepatocellular Carcinoma Using N-(4-(6,7-dimethoxyquinolin-4-yloxy)phenyl)-N′-(4-fluorophenyl)cyclopropane-1,1-dicarboxamide, (2S)-hydroxybutanedioate |
JP7321165B2 (en) * | 2018-01-26 | 2023-08-04 | エグゼリクシス, インコーポレイテッド | Compounds for treating kinase dependent disorders |
MX2020007759A (en) * | 2018-01-26 | 2020-09-24 | Exelixis Inc | Compounds for the treatment of kinase-dependent disorders. |
EP3743417A1 (en) * | 2018-01-26 | 2020-12-02 | Exelixis, Inc. | Compounds for the treatment of kinase-dependent disorders |
KR20200116945A (en) | 2018-02-02 | 2020-10-13 | 반더빌트유니버시티 | Antagonist of muscarinic acetylcholine receptor M4 |
CN108264482A (en) * | 2018-02-05 | 2018-07-10 | 南京法恩化学有限公司 | It is a kind of to block the rich preparation method for Buddhist nun |
PL3750893T3 (en) | 2018-02-11 | 2023-07-17 | Beijing Scitech-Mq Pharmaceuticals Limited | Dioxazoline compound, preparation method therefor, and uses thereof |
WO2019180141A1 (en) | 2018-03-23 | 2019-09-26 | Bayer Aktiengesellschaft | Combinations of rogaratinib |
WO2019234761A1 (en) | 2018-06-05 | 2019-12-12 | Natco Pharma Limited | An improved process for the preparation of cabozantinib and its pharmaceutically acceptable salts thereof |
EP3806858A4 (en) | 2018-06-15 | 2022-03-09 | Handa Pharmaceuticals, Inc. | Kinase inhibitor salts and compositions thereof |
US11702425B2 (en) * | 2018-08-01 | 2023-07-18 | Agency For Science, Technology And Research | Bicyclic compounds as kinase modulators, methods and uses thereof |
CN110862398B (en) * | 2018-08-27 | 2021-04-06 | 北京赛特明强医药科技有限公司 | Urea substituted aromatic ring-linked dioxane quinazoline or quinoline compound, composition and application thereof |
WO2020075196A1 (en) | 2018-10-11 | 2020-04-16 | Cipla Limited | Polymorphs of n-(4-(6,7-dimethoxyquinolin-4-yloxy) phenyl)-n'-(4-fluorophenyl)cyclopropane-1, 1-dicarboxamide, (s)- malate, methods of production and pharmaceutical uses thereof |
CN111303024B (en) * | 2018-12-12 | 2023-03-28 | 安徽中科拓苒药物科学研究有限公司 | Quinoline-structured pan-KIT kinase inhibitor and application thereof |
EP3894012A1 (en) * | 2018-12-13 | 2021-10-20 | Exelixis, Inc. | Crystalline forms and salt forms of a kinase inhibitor |
TW202038957A (en) | 2018-12-21 | 2020-11-01 | 日商第一三共股份有限公司 | Combination of antibody-drug conjugate and kinase inhibitor |
WO2020210481A1 (en) * | 2019-04-12 | 2020-10-15 | Nation Health Research Institutes | Heterocyclic compounds as kinase inhibitors for therapeutic uses |
CN111825609A (en) * | 2019-04-22 | 2020-10-27 | 北京康辰药业股份有限公司 | Compound crystal form, preparation method, pharmaceutical composition and application thereof |
WO2020247019A1 (en) * | 2019-06-03 | 2020-12-10 | Exelixis, Inc. | Crystalline salt forms of a kinase inhibitor |
CN110117254B (en) * | 2019-06-20 | 2022-05-13 | 江苏君若药业有限公司 | Preparation method of cabozantinib |
CN112778217B (en) * | 2019-11-08 | 2024-01-26 | 沈阳化工研究院有限公司 | Quinazoline compound and application thereof |
CN111393363B (en) * | 2020-04-27 | 2022-12-20 | 威海海洋生物医药产业技术研究院有限公司 | 4-phenoxy quinoline and N-sulfonyl amidine compound and preparation method and application thereof |
CN113577066B (en) * | 2020-04-30 | 2022-12-16 | 中国科学院上海药物研究所 | Use of arylguanidine compounds or pharmaceutically acceptable salts thereof |
IT202000027678A1 (en) | 2020-11-18 | 2022-05-18 | Indena Spa | CABOZANTINIB-(S)-MALATO AMORPHOUS SOLID DISPERSIONS AND PROCESSES FOR THEIR PREPARATION |
CA3202761A1 (en) | 2020-11-25 | 2022-06-02 | Nanocopoeia, Llc | Amorphous cabozantinib particles and uses thereof |
IL303655A (en) * | 2020-12-17 | 2023-08-01 | Astrazeneca Ab | N-(2-(4-cyanothiazolidin-3-yl)-2-oxoethyl)- quinoline-4-carboxamides |
CA3213086A1 (en) * | 2021-03-24 | 2022-09-29 | Ramakrishna Parameshwar Bhat | Process for preparation of cabozantinib |
WO2023081923A1 (en) | 2021-11-08 | 2023-05-11 | Frequency Therapeutics, Inc. | Platelet-derived growth factor receptor (pdgfr) alpha inhibitors and uses thereof |
WO2023098853A1 (en) * | 2021-12-03 | 2023-06-08 | 湖南湘源美东医药科技有限公司 | Cocrystal of cabozantinib, preparation method therefor and application thereof as drug or in pharmaceutical preparation |
CN114605391B (en) * | 2022-02-21 | 2024-01-26 | 广州六顺生物科技股份有限公司 | Quinoxaline derivative, preparation method and application thereof |
WO2023165948A1 (en) | 2022-03-01 | 2023-09-07 | Synthon B.V. | Cabozantinib salt with l-(+)-tartaric acid and solid forms thereof |
WO2023222946A1 (en) | 2022-05-18 | 2023-11-23 | Fermion Oy | Process for the preparation of cabozantinib |
WO2023228095A1 (en) | 2022-05-24 | 2023-11-30 | Daiichi Sankyo Company, Limited | Dosage regimen of an anti-cdh6 antibody-drug conjugate |
WO2024008929A1 (en) | 2022-07-08 | 2024-01-11 | Astrazeneca Ab | Epidermal growth factor receptor tyrosine kinase inhibitors in combination with hgf-receptor inhibitors for the treatment of cancer |
Family Cites Families (170)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US506181A (en) | 1893-10-03 | Folding crate | ||
GB2160201B (en) * | 1984-06-14 | 1988-05-11 | Wyeth John & Brother Ltd | Quinazoline and cinnoline derivatives |
US5123951A (en) * | 1986-03-31 | 1992-06-23 | Rhone-Poulenc Nederland B.V. | Synergistic plant growth regulator compositions |
JPS646261A (en) * | 1987-03-31 | 1989-01-10 | Nisshin Flour Milling Co | 4-thioquinazoline derivative, its production and antiulcer agent containing said derivative as active component |
US5143854A (en) * | 1989-06-07 | 1992-09-01 | Affymax Technologies N.V. | Large scale photolithographic solid phase synthesis of polypeptides and receptor binding screening thereof |
US5034393A (en) * | 1989-07-27 | 1991-07-23 | Dowelanco | Fungicidal use of pyridopyrimidine, pteridine, pyrimidopyrimidine, pyrimidopyridazine, and pyrimido-1,2,4-triazine derivatives |
US5238951A (en) | 1991-02-01 | 1993-08-24 | E. R. Squibb & Sons, Inc. | Heterocyclic amido prostaglandin analogs |
DE4114733A1 (en) * | 1991-05-06 | 1992-11-12 | Huels Chemische Werke Ag | METHOD FOR PRODUCING SUBSTITUTED MALONESTERANILIDES AND MALONIC ACID MONOANILIDES |
US5710158A (en) * | 1991-05-10 | 1998-01-20 | Rhone-Poulenc Rorer Pharmaceuticals Inc. | Aryl and heteroaryl quinazoline compounds which inhibit EGF and/or PDGF receptor tyrosine kinase |
US5480883A (en) * | 1991-05-10 | 1996-01-02 | Rhone-Poulenc Rorer Pharmaceuticals Inc. | Bis mono- and bicyclic aryl and heteroaryl compounds which inhibit EGF and/or PDGF receptor tyrosine kinase |
US5358941A (en) | 1992-12-02 | 1994-10-25 | Merck & Co., Inc. | Dry mix formulation for bisphosphonic acids with lactose |
US6498144B1 (en) | 1993-10-18 | 2002-12-24 | North Shore - Long Island Jewish Research Institute | Use of scatter factor to enhance angiogenesis |
IL112249A (en) | 1994-01-25 | 2001-11-25 | Warner Lambert Co | Pharmaceutical compositions containing di and tricyclic pyrimidine derivatives for inhibiting tyrosine kinases of the epidermal growth factor receptor family and some new such compounds |
GB9510757D0 (en) | 1994-09-19 | 1995-07-19 | Wellcome Found | Therapeuticaly active compounds |
TW321649B (en) | 1994-11-12 | 1997-12-01 | Zeneca Ltd | |
GB9508538D0 (en) | 1995-04-27 | 1995-06-14 | Zeneca Ltd | Quinazoline derivatives |
US5747498A (en) | 1996-05-28 | 1998-05-05 | Pfizer Inc. | Alkynyl and azido-substituted 4-anilinoquinazolines |
US5650415A (en) | 1995-06-07 | 1997-07-22 | Sugen, Inc. | Quinoline compounds |
DK1090642T3 (en) | 1995-06-07 | 2008-09-22 | Glaxosmithkline Biolog Sa | Vaccines comprising a polysaccharide antigen carrier protein conjugate and free carrier protein |
AU5984296A (en) | 1995-06-07 | 1996-12-30 | Sugen, Inc. | Quinazolines and pharmaceutical compositions |
GB9514265D0 (en) | 1995-07-13 | 1995-09-13 | Wellcome Found | Hetrocyclic compounds |
DE69622183D1 (en) * | 1995-11-07 | 2002-08-08 | Kirin Brewery | CHINOLINE DERIVATIVES AND CHINAZOLE DERIVATIVES, WHICH INHIBIT THE AUTOPHOSPHORYLATION OF THE GROWTH FACTOR RECEPTOR DERIVING FROM BLOOD PLATPLES AND THEIR PHARMACEUTICAL COMPOSITIONS CONTAINING THEM |
GB9523675D0 (en) | 1995-11-20 | 1996-01-24 | Celltech Therapeutics Ltd | Chemical compounds |
GB9624482D0 (en) | 1995-12-18 | 1997-01-15 | Zeneca Phaema S A | Chemical compounds |
GB9526546D0 (en) | 1995-12-23 | 1996-02-28 | Pfizer Ltd | Compounds useful in therapy |
JP4471404B2 (en) | 1996-02-13 | 2010-06-02 | アストラゼネカ ユーケイ リミテッド | Quinazoline derivatives as VEGF inhibitors |
GB9603095D0 (en) | 1996-02-14 | 1996-04-10 | Zeneca Ltd | Quinazoline derivatives |
PT885198E (en) | 1996-03-05 | 2002-06-28 | Astrazeneca Ab | 4-ANYLINOQUINAZOLINE DERIVATIVES |
WO1997034876A1 (en) | 1996-03-15 | 1997-09-25 | Zeneca Limited | Cinnoline derivatives and use as medicine |
US6107300A (en) | 1996-03-27 | 2000-08-22 | Dupont Pharmaceuticals | Arylamino fused pyrimidines |
NZ332119A (en) | 1996-04-12 | 2001-08-31 | Warner Lambert Co | Quinazoline compounds which are irreversible inhibitors of tyrosine kinases |
HRP970371A2 (en) | 1996-07-13 | 1998-08-31 | Kathryn Jane Smith | Heterocyclic compounds |
AR007857A1 (en) | 1996-07-13 | 1999-11-24 | Glaxo Group Ltd | HETERO-CYCLIC COMPOUNDS FUSED AS PROTEIN INHIBITORS, THYROSINE KINASE, THEIR PREPARATION METHODS, INTERMEDIARY USE IN MEDICINE AND PHARMACEUTICAL COMPOSITIONS CONTAINING THEM. |
WO1998013350A1 (en) | 1996-09-25 | 1998-04-02 | Zeneca Limited | Qinoline derivatives inhibiting the effect of growth factors such as vegf |
GB9718972D0 (en) | 1996-09-25 | 1997-11-12 | Zeneca Ltd | Chemical compounds |
KR100622323B1 (en) | 1996-10-01 | 2006-11-30 | 교와 핫꼬 고교 가부시끼가이샤 | Nitrogenous heterocyclic compounds |
GB9700504D0 (en) | 1997-01-11 | 1997-02-26 | Pfizer Ltd | Pharmaceutical compounds |
GB9705361D0 (en) | 1997-03-14 | 1997-04-30 | Celltech Therapeutics Ltd | Chemical compounds |
UA73073C2 (en) | 1997-04-03 | 2005-06-15 | Уайт Холдінгз Корпорейшн | Substituted 3-cyan chinolines |
ATE244225T1 (en) | 1997-04-18 | 2003-07-15 | Kirin Brewery | METHOD FOR PRODUCING QUINOLINE DERIVATIVES |
WO1998047874A1 (en) | 1997-04-22 | 1998-10-29 | Janssen Pharmaceutica N.V. | Crf antagonistic quino- and quinazolines |
GB9708917D0 (en) | 1997-05-01 | 1997-06-25 | Pfizer Ltd | Compounds useful in therapy |
AR012634A1 (en) | 1997-05-02 | 2000-11-08 | Sugen Inc | QUINAZOLINE BASED COMPOUND, FAMACEUTICAL COMPOSITION THAT UNDERSTANDS IT, METHOD TO SYNTHESIZE IT, ITS USE, METHODS OF MODULATION OF THE DESERINE / TREONIN PROTEIN-KINASE FUNCTION AND IN VITRO METHOD TO IDENTIFY COMPOUNDS THAT MODULATE |
ZA986732B (en) | 1997-07-29 | 1999-02-02 | Warner Lambert Co | Irreversible inhibitiors of tyrosine kinases |
AU8816298A (en) | 1997-08-22 | 1999-03-16 | Zeneca Limited | Oxindolylquinazoline derivatives as angiogenesis inhibitors |
JP4194678B2 (en) * | 1997-11-28 | 2008-12-10 | キリンファーマ株式会社 | Quinoline derivative and pharmaceutical composition containing the same |
GB9800569D0 (en) | 1998-01-12 | 1998-03-11 | Glaxo Group Ltd | Heterocyclic compounds |
HUP0102793A3 (en) | 1998-05-28 | 2002-07-29 | Parker Hughes Inst St Paul | Quinazolines for treating brain tumor and medicaments containing them |
CN1152031C (en) | 1998-08-11 | 2004-06-02 | 诺瓦提斯公司 | Isoquinoline derivatives with angiogenesis inhibiting activity |
IL141434A0 (en) | 1998-08-21 | 2002-03-10 | Parker Hughes Inst | Quinazoline derivatives |
US6184226B1 (en) | 1998-08-28 | 2001-02-06 | Scios Inc. | Quinazoline derivatives as inhibitors of P-38 α |
AU5404399A (en) | 1998-09-10 | 2000-04-03 | Ipr-Institute For Pharmaceutical Research Ag | Topical application products |
US6288082B1 (en) * | 1998-09-29 | 2001-09-11 | American Cyanamid Company | Substituted 3-cyanoquinolines |
IL142121A0 (en) | 1998-09-29 | 2002-03-10 | American Cyanamid Co | Substituted 3-cyanoquinolines as protein tyrosine kinases inhibitors |
KR20010089284A (en) | 1998-10-01 | 2001-09-29 | 다비드 에 질레스 | Chemical compounds |
CA2344290C (en) | 1998-10-08 | 2009-06-02 | Astrazeneca Ab | Quinazoline derivatives |
DE69904358T2 (en) | 1998-11-19 | 2003-04-17 | Warner Lambert Co | N- 4- (3-CHLORO-4-FLUORO-PHENYLAMINO) -7- (3-MORFOLIN-4-YL-PROPOXY) -CHINAZININ-6-YL-ACRYLAMIDE, AN IRREVERSIBLE TYROSINE-KINASEN HEMMER |
DE60033857T2 (en) * | 1999-01-22 | 2007-10-25 | Kirin Beer K.K. | Derivatives of the N - ((quinolinyl) oxy) phenyl) urea and the N - ((quinazolinyl) oxy) -phenyl) urea with antitumor activity |
KR100838617B1 (en) | 1999-02-10 | 2008-06-16 | 아스트라제네카 아베 | Quinazoline derivatives as angiogenesis inhibitors |
GB9904103D0 (en) | 1999-02-24 | 1999-04-14 | Zeneca Ltd | Quinoline derivatives |
US6080747A (en) | 1999-03-05 | 2000-06-27 | Hughes Institute | JAK-3 inhibitors for treating allergic disorders |
DE19911509A1 (en) | 1999-03-15 | 2000-09-21 | Boehringer Ingelheim Pharma | Bicyclic heterocycles, medicaments containing these compounds, their use and processes for their preparation |
EP1162974A1 (en) | 1999-03-19 | 2001-12-19 | Parker Hughes Institute | Quinazoline formulations and therapeutic use thereof |
US6258820B1 (en) | 1999-03-19 | 2001-07-10 | Parker Hughes Institute | Synthesis and anti-tumor activity of 6,7-dialkoxy-4-phenylamino-quinazolines |
RS49836B (en) | 1999-03-31 | 2008-08-07 | Pfizer Products Inc., | Process and intermediates for preparing anti-cancer compounds |
GB9910577D0 (en) | 1999-05-08 | 1999-07-07 | Zeneca Ltd | Chemical compounds |
GB9910580D0 (en) * | 1999-05-08 | 1999-07-07 | Zeneca Ltd | Chemical compounds |
US6126917A (en) | 1999-06-01 | 2000-10-03 | Hadasit Medical Research Services And Development Ltd. | Epidermal growth factor receptor binding compounds for positron emission tomography |
UA71976C2 (en) | 1999-06-21 | 2005-01-17 | Boehringer Ingelheim Pharma | Bicyclic heterocycles and a medicament based thereon |
RU2002110461A (en) * | 1999-09-21 | 2004-03-10 | Астразенека Аб (Se) | Quinazoline derivatives and their use as pharmaceutical substances |
GB9922171D0 (en) | 1999-09-21 | 1999-11-17 | Zeneca Ltd | Chemical compounds |
US6759410B1 (en) | 1999-11-23 | 2004-07-06 | Smithline Beecham Corporation | 3,4-dihydro-(1H)-quinazolin-2-ones and their use as CSBP/p38 kinase inhibitors |
AU4903201A (en) | 1999-11-30 | 2001-07-03 | Parker Hughes Institute | Inhibitors of thrombin induced platelet aggregation |
US20020002169A1 (en) | 1999-12-08 | 2002-01-03 | Griffin John H. | Protein kinase inhibitors |
US7135466B2 (en) * | 1999-12-24 | 2006-11-14 | Kirin Beer Kabushiki Kaisha | Quinoline and quinazoline derivatives and drugs containing the same |
US6525046B1 (en) | 2000-01-18 | 2003-02-25 | Boehringer Ingelheim Pharmaceuticals, Inc. | Aromatic heterocyclic compounds as antiinflammatory agents |
AU2001228638A1 (en) * | 2000-01-28 | 2001-08-07 | Astrazeneca Ab | Chemical compounds |
US6664390B2 (en) | 2000-02-02 | 2003-12-16 | Warner-Lambert Company Llc | Method for the simplified production of (3-chloro-4-fluorophenyl)-[7-(3-morpholin-4-yl-propoxy)-6-nitro-quinazoline-4-yl]-amine or (3-chloro-4-fluorophenyl)-[7-(3-morpholin-4-yl-propoxy)-6-amino-quinazoline-4-yl]-amine |
US7091227B2 (en) | 2000-02-07 | 2006-08-15 | Abbott Gmbh & Co. Kg | Benzothiazole derivatives |
KR20080009294A (en) | 2000-03-13 | 2008-01-28 | 와이어쓰 홀딩스 코포레이션 | Pharmaceutical composition for treating or inhibiting colonic polyps comprising cyanoquinolines |
US6608048B2 (en) | 2000-03-28 | 2003-08-19 | Wyeth Holdings | Tricyclic protein kinase inhibitors |
US6521618B2 (en) | 2000-03-28 | 2003-02-18 | Wyeth | 3-cyanoquinolines, 3-cyano-1,6-naphthyridines, and 3-cyano-1,7-naphthyridines as protein kinase inhibitors |
US6627634B2 (en) | 2000-04-08 | 2003-09-30 | Boehringer Ingelheim Pharma Kg | Bicyclic heterocycles, pharmaceutical compositions containing them, their use, and processes for preparing them |
UA73993C2 (en) | 2000-06-06 | 2005-10-17 | Астразенека Аб | Quinazoline derivatives for the treatment of tumours and a pharmaceutical composition |
HUP0301120A2 (en) | 2000-06-22 | 2003-08-28 | Pfizer Products Inc. | Substituted phenylamino-quinazolin derivatives, their use for the treatment of abnormal cell growth and pharmaceutical compositions containing them |
US6919338B2 (en) | 2000-06-28 | 2005-07-19 | Astrazeneca Ab | Substituted quinazoline derivatives and their use as inhibitors of aurora-2 kinase |
EP1174118A1 (en) | 2000-06-28 | 2002-01-23 | Cognis France S.A. | Use of inulin and derivatives thereof |
FR2811658B1 (en) | 2000-07-17 | 2004-07-02 | Cfpi Nufarm | BIOLOGICAL REACTOR WITH SUBMERGED FIXED BED AND METHOD FOR TREATING LIQUID EFFLUENTS |
JP2002030083A (en) * | 2000-07-18 | 2002-01-29 | Kirin Brewery Co Ltd | N-(2-chloro-4-{[6-methoxy-7-(3-pyridylmethoxy)-4- quinolyl]oxy}phenyl)-n'-propylurea dihydrochloride |
CA2417500C (en) * | 2000-07-28 | 2008-11-18 | Georgetown University Medical Center | Erbb-2 selective small molecule kinase inhibitors |
AU7860901A (en) | 2000-08-21 | 2002-03-04 | Astrazeneca Ab | Quinazoline derivatives |
US6403580B1 (en) | 2000-08-26 | 2002-06-11 | Boehringer Ingelheim Pharma Kg | Quinazolines, pharmaceutical compositions containing these compounds, their use and processes for preparing them |
US6617329B2 (en) | 2000-08-26 | 2003-09-09 | Boehringer Ingelheim Pharma Kg | Aminoquinazolines and their use as medicaments |
US6653305B2 (en) | 2000-08-26 | 2003-11-25 | Boehringer Ingelheim Pharma Kg | Bicyclic heterocycles, pharmaceutical compositions containing them, their use, and processes for preparing them |
US6656946B2 (en) | 2000-08-26 | 2003-12-02 | Boehringer Ingelheim Pharma Kg | Aminoquinazolines which inhibit signal transduction mediated by tyrosine kinases |
US6740651B2 (en) | 2000-08-26 | 2004-05-25 | Boehringer Ingelheim Pharma Kg | Aminoquinazolines which inhibit signal transduction mediated by tyrosine kinases |
DE10042058A1 (en) | 2000-08-26 | 2002-03-07 | Boehringer Ingelheim Pharma | Bicyclic heterocycles, medicaments containing these compounds, their use and processes for their preparation |
AU2001292138A1 (en) | 2000-10-13 | 2002-04-22 | Astrazeneca Ab | Quinazoline derivatives with anti-tumour activity |
WO2002030926A1 (en) | 2000-10-13 | 2002-04-18 | Astrazeneca Ab | Quinazoline derivatives |
NZ525324A (en) * | 2000-10-20 | 2005-03-24 | Eisai Co Ltd | Nitrogenous aromatic ring compounds |
JP2004512335A (en) | 2000-10-25 | 2004-04-22 | アストラゼネカ アクチボラグ | Quinazoline derivatives |
EP1337524A1 (en) | 2000-11-02 | 2003-08-27 | AstraZeneca AB | Substituted quinolines as antitumor agents |
US7253184B2 (en) | 2000-11-02 | 2007-08-07 | Astrazeneca Ab | 4-Substituted quinolines as antitumor agents |
WO2002036577A1 (en) | 2000-11-02 | 2002-05-10 | Nippon Shinyaku Co., Ltd. | Quinazoline derivatives and drugs |
US7019012B2 (en) | 2000-12-20 | 2006-03-28 | Boehringer Ingelheim International Pharma Gmbh & Co. Kg | Quinazoline derivatives and pharmaceutical compositions containing them |
US6900220B2 (en) | 2001-01-02 | 2005-05-31 | Syntex (U.S.A.) Llc | Quinazolone derivatives as alpha 1A/B adrenergic receptor antagonists |
DE60229046D1 (en) | 2001-04-19 | 2008-11-06 | Astrazeneca Ab | CHINAZOLINE DERIVATIVES |
DE60208364T2 (en) * | 2001-04-27 | 2006-09-28 | Kirin Beer K.K. | CHINOLINE DERIVATIVES WITH AN AZOLYL GROUP AND CHINAZOLINE DERIVATIVES |
SE0101675D0 (en) | 2001-05-11 | 2001-05-11 | Astrazeneca Ab | Novel composition |
WO2002092579A1 (en) | 2001-05-14 | 2002-11-21 | Astrazeneca Ab | 4-anilinoquinazoline derivatives |
WO2002092577A1 (en) | 2001-05-14 | 2002-11-21 | Astrazeneca Ab | Quinazoline derivatives |
WO2002092578A1 (en) | 2001-05-14 | 2002-11-21 | Astrazeneca Ab | Quinazoline derivatives |
US6734303B2 (en) | 2001-05-18 | 2004-05-11 | Pfizer Inc. | Process for the production of quinazolines |
DE10125432A1 (en) * | 2001-05-25 | 2002-11-28 | Bayer Ag | New benzoyl-substituted aliphatic ketones or aldehydes, useful as herbicides or fungicides, especially as pre- and post-emergence selective herbicides against a broad spectrum of weeds |
AU2002350105A1 (en) | 2001-06-21 | 2003-01-08 | Ariad Pharmaceuticals, Inc. | Novel quinazolines and uses thereof |
US7425564B2 (en) * | 2001-06-22 | 2008-09-16 | Kirin Beer Kabushiki Kaisha | Quinoline derivative and quinazoline derivative inhibiting self-phosphorylation of hepatocytus prolifertor receptor and medicinal composition containing the same |
KR100397792B1 (en) | 2001-06-28 | 2003-09-13 | 한국과학기술연구원 | 4-(phenylamino)-[1,4]dioxano[2,3-g]quinazoline Derivatives and Process for Preparing the Same |
GB0118752D0 (en) | 2001-08-01 | 2001-09-26 | Pfizer Ltd | Process for the production of quinazolines |
US7229774B2 (en) | 2001-08-02 | 2007-06-12 | Regents Of The University Of Michigan | Expression profile of prostate cancer |
US20030066060A1 (en) | 2001-09-28 | 2003-04-03 | Ford Richard L. | Cross profile guided optimization of program execution |
JP4383870B2 (en) | 2001-10-17 | 2009-12-16 | 協和発酵キリン株式会社 | Quinoline derivatives and quinazoline derivatives that inhibit fibroblast growth factor receptor autophosphorylation and pharmaceutical compositions containing them |
WO2003037252A2 (en) | 2001-10-30 | 2003-05-08 | Merck & Co., Inc. | Tyrosine kinase inhibitors |
GB0126433D0 (en) | 2001-11-03 | 2002-01-02 | Astrazeneca Ab | Compounds |
GB0128108D0 (en) | 2001-11-23 | 2002-01-16 | Astrazeneca Ab | Therapeutic use |
AR037438A1 (en) | 2001-11-27 | 2004-11-10 | Wyeth Corp | 3-CYANOKINOLINES AS INHIBITORS OF EGF-R AND HER2 KINASES, A PROCESS FOR THEIR PREPARATION, PHARMACEUTICAL COMPOSITIONS AND THE USE OF SUCH COMPOUNDS FOR THE MANUFACTURE OF MEDICINES |
AU2002347359A1 (en) | 2001-12-05 | 2003-06-17 | Astrazeneca Ab | Quinoline derivatives |
WO2003048159A1 (en) | 2001-12-05 | 2003-06-12 | Astrazeneca Ab | Quinoline derivatives |
GB0129099D0 (en) | 2001-12-05 | 2002-01-23 | Astrazeneca Ab | Chemical compounds |
EA200400680A1 (en) | 2001-12-12 | 2005-06-30 | Пфайзер Продактс Инк. | HINAZOLINA DERIVATIVES FOR THE TREATMENT OF ANOMALOUS GROWTH OF CELLS |
AU2002366581A1 (en) | 2001-12-12 | 2003-06-23 | Pfizer Products Inc. | Salt forms of E-2-methoxy-N-(3-(4-(3-methyl-pyridin-3-yloxy)-phenylamino)-quinazolin-6-yl)-allyl)-acetamide, its preparation and its use against cancer |
WO2003055866A1 (en) | 2001-12-21 | 2003-07-10 | Bayer Pharmaceuticals Corporation | Quinazoline and quinoline derivative compounds as inhibitors of prolylpeptidase, inducers of apoptosis and cancer treatment agents |
TW200301123A (en) | 2001-12-21 | 2003-07-01 | Astrazeneca Uk Ltd | New use |
UA82058C2 (en) | 2001-12-24 | 2008-03-11 | Астразенека Аб | Substituted quinazoline derivatives as inhibitors of aurora kinases, process for preparation thereof, pharmaceutical composition containing them |
EP1470125A1 (en) | 2002-01-29 | 2004-10-27 | Glaxo Group Limited | Aminopiperidine derivatives |
US7109213B2 (en) | 2002-01-29 | 2006-09-19 | Glaxo Group Limited | Aminopiperidine compounds, process for their preparation, and pharmaceutical compositions containing them |
ES2381781T3 (en) | 2002-02-01 | 2012-05-31 | Astrazeneca Ab | Quinazoline Compounds |
DE10204462A1 (en) | 2002-02-05 | 2003-08-07 | Boehringer Ingelheim Pharma | Use of tyrosine kinase inhibitors for the treatment of inflammatory processes |
WO2003074497A1 (en) * | 2002-03-01 | 2003-09-12 | Pintex Pharmaceutical, Inc. | Pin1-modulating compounds and methods of use thereof |
DE10217689A1 (en) | 2002-04-19 | 2003-11-13 | Boehringer Ingelheim Pharma | Bicyclic heterocycles, medicaments containing these compounds, their use and processes for their preparation |
AU2003235838A1 (en) * | 2002-05-01 | 2003-11-17 | Kirin Beer Kabushiki Kaisha | Quinoline derivatives and quinazoline derivatives inhibiting autophosphorylation of macrophage colony stimulating factor receptor |
US7576074B2 (en) | 2002-07-15 | 2009-08-18 | Rice Kenneth D | Receptor-type kinase modulators and methods of use |
JPWO2004018430A1 (en) * | 2002-08-23 | 2005-12-08 | 麒麟麦酒株式会社 | Compound having TGFβ inhibitory activity and pharmaceutical composition comprising the same |
GB0219746D0 (en) | 2002-08-23 | 2002-10-02 | Inst Of Ex Botany Ascr | Azapurine derivatives |
ES2294317T3 (en) | 2002-10-21 | 2008-04-01 | Kirin Pharma Kabushiki Kaisha | SALT OF N- (2-CHLORINE-4 - ((6,7-DIMETOXI-4-QUINOLIL) OXI) PHENYL) -N '- (5-METHYL-3-ISOXAZOLIL) CRYSTALLINE UREA. |
US20080207617A1 (en) * | 2002-10-29 | 2008-08-28 | Kirin Beer Kabushiki Kaisha | Quinoline Derivatives and Quinazoline Derivatives Inhibiting Autophosphrylation of Flt3 and Medicinal Compositions Containing the Same |
RU2350618C2 (en) | 2002-11-04 | 2009-03-27 | Астразенека Аб | QUINAZOLINE DERIVATIVES AS Src TYROSINE KINASE INHIBITORS |
AU2003300898A1 (en) | 2002-12-13 | 2004-07-09 | Neurogen Corporation | Carboxylic acid, phosphate or phosphonate substituted quinazolin-4-ylamine analogues as capsaicin receptor modulators |
BR0317433A (en) | 2002-12-18 | 2005-11-16 | Pfizer Prod Inc | Bicyclic Derivatives for the Treatment of Abnormal Cell Growth |
US7238679B2 (en) | 2002-12-23 | 2007-07-03 | Ariad Pharmaceuticals, Inc. | Heterocycles and uses thereof |
WO2004060373A1 (en) * | 2002-12-27 | 2004-07-22 | Santen Pharmaceutical Co., Ltd. | Therapeutic agent for wet age-related macular degeneration |
US8176532B1 (en) * | 2003-03-17 | 2012-05-08 | Sprint Communications Company L.P. | Secure access point for scada devices |
KR100559180B1 (en) * | 2003-05-20 | 2006-03-14 | 김민서 | Electronic settlement method and server according to conditional trade |
WO2005003140A1 (en) | 2003-07-02 | 2005-01-13 | Pharmacia & Upjohn Company Llc | 4-oxo-4,7-dihydrothieno[2,3-b]pyridine-5-carboxamides as antiviral agents |
JP4750701B2 (en) | 2003-07-07 | 2011-08-17 | メルク パテント ゲゼルシャフト ミット ベシュレンクテル ハフツング | Malonamide derivatives |
CA2537812C (en) | 2003-09-26 | 2013-01-22 | Exelixis, Inc. | C-met modulators and method of use |
EP1711495A2 (en) | 2004-01-23 | 2006-10-18 | Amgen Inc. | Quinoline, quinazoline, pyridine and pyrimidine counds and their use in the treatment of inflammation, angiogenesis and cancer |
US7173031B2 (en) * | 2004-06-28 | 2007-02-06 | Bristol-Myers Squibb Company | Pyrrolotriazine kinase inhibitors |
AU2005270068B2 (en) * | 2004-07-02 | 2012-04-19 | Exelixis, Inc. | C-Met modulators and method of use |
WO2006108059A1 (en) * | 2005-04-06 | 2006-10-12 | Exelixis, Inc. | C-met modulators and methods of use |
US7594258B2 (en) * | 2005-06-27 | 2009-09-22 | Yahoo! Inc. | Access control systems and methods using visibility tokens with automatic propagation |
WO2008035209A2 (en) * | 2006-05-30 | 2008-03-27 | Methylgene Inc. | Inhibitors of protein tyrosine kinase activity |
JP2012504606A (en) | 2008-10-01 | 2012-02-23 | ラディック インスティテュート フォー キャンサー リサーチ | How to treat cancer |
CN102239148A (en) | 2008-12-04 | 2011-11-09 | 埃克塞里艾克西斯公司 | Methods of preparing quinoline derivatives |
EA019959B1 (en) | 2009-01-16 | 2014-07-30 | Экселиксис, Инк. | Malate salt of n-(4-{[6,7-bis(methyloxy)quin0lin-4-yl]oxy}phenyl)-n'-(4-fluorophenyl)cyclopropane-1,1-dicarboxamide, and crystalline forms thereof for the treatment of cancer |
NZ597695A (en) | 2009-07-17 | 2014-05-30 | Exelixis Inc | Crystalline forms of n-[3-fluoro-4-({ 6-(methyloxy)-7-[(3-morpholin-4-ylpropyl)oxy]-quinolin-4-yl} oxy)phenyl]-n’-(4-fluorophenyl)cyclopropane-1, 1-dicarboxamide |
UA108618C2 (en) | 2009-08-07 | 2015-05-25 | APPLICATION OF C-MET-MODULATORS IN COMBINATION WITH THEMOSOLOMID AND / OR RADIATION THERAPY FOR CANCER TREATMENT | |
WO2011031840A1 (en) | 2009-09-09 | 2011-03-17 | Quintiles Transnational Corp. | Methods and compositions for the treatment of receptor tyrosine kinase mediated diseases or disorders |
JP5461213B2 (en) | 2010-01-29 | 2014-04-02 | 三洋電機株式会社 | Air conditioner outdoor unit |
US20120070368A1 (en) | 2010-04-16 | 2012-03-22 | Exelixis, Inc. | Methods of Using C-Met Modulators |
US20120252840A1 (en) | 2011-04-04 | 2012-10-04 | Exelixis, Inc. | Method of Treating Cancer |
-
2004
- 2004-09-24 CA CA2537812A patent/CA2537812C/en active Active
- 2004-09-24 DK DK10160518.6T patent/DK2213661T3/en active
- 2004-09-24 SI SI200432122T patent/SI2392564T1/en unknown
- 2004-09-24 EP EP17190013.7A patent/EP3329918B1/en active Active
- 2004-09-24 EP EP04789057A patent/EP1673085B1/en active Active
- 2004-09-24 EP EP11179942.5A patent/EP2392565B1/en active Active
- 2004-09-24 ES ES10160518T patent/ES2369652T3/en active Active
- 2004-09-24 EP EP10160518A patent/EP2213661B1/en active Active
- 2004-09-24 EP EP11179941.7A patent/EP2392564B1/en active Active
- 2004-09-24 EP EP10160517A patent/EP2210607B1/en active Active
- 2004-09-24 AU AU2004275842A patent/AU2004275842B2/en not_active Ceased
- 2004-09-24 ES ES17190013T patent/ES2925655T3/en active Active
- 2004-09-24 EP EP13151957.1A patent/EP2609919A3/en not_active Withdrawn
- 2004-09-24 SI SI200431754T patent/SI2210607T1/en unknown
- 2004-09-24 WO PCT/US2004/031523 patent/WO2005030140A2/en active Application Filing
- 2004-09-24 DK DK11179941.7T patent/DK2392564T3/en active
- 2004-09-24 ES ES11179942.5T patent/ES2466818T3/en active Active
- 2004-09-24 ES ES10160517T patent/ES2371383T3/en active Active
- 2004-09-24 PT PT10160518T patent/PT2213661E/en unknown
- 2004-09-24 SI SI200431746T patent/SI2213661T1/en unknown
- 2004-09-24 EP EP11179944.1A patent/EP2409704B1/en active Active
- 2004-09-24 EP EP13151945.6A patent/EP2612853A1/en not_active Withdrawn
- 2004-09-24 JP JP2006528265A patent/JP4638436B2/en not_active Expired - Fee Related
- 2004-09-24 CA CA2744997A patent/CA2744997A1/en not_active Abandoned
- 2004-09-24 PL PL11179942T patent/PL2392565T3/en unknown
- 2004-09-24 PT PT10160517T patent/PT2210607E/en unknown
- 2004-09-24 PL PL10160518T patent/PL2213661T3/en unknown
- 2004-09-24 AT AT04789057T patent/ATE532782T1/en active
- 2004-09-24 SI SI200432145T patent/SI2392565T1/en unknown
- 2004-09-24 ES ES11179941.7T patent/ES2436888T3/en active Active
- 2004-09-24 DK DK11179942.5T patent/DK2392565T3/en active
- 2004-09-24 DK DK10160517.8T patent/DK2210607T3/en active
- 2004-09-24 AT AT10160518T patent/ATE517091T1/en active
- 2004-09-24 AT AT10160517T patent/ATE520403T1/en active
- 2004-09-24 ES ES11179944.1T patent/ES2651730T3/en active Active
- 2004-09-24 PL PL10160517T patent/PL2210607T3/en unknown
-
2006
- 2006-10-26 US US11/586,751 patent/US9174947B2/en active Active
-
2007
- 2007-05-24 US US11/753,462 patent/US8178532B2/en active Active
- 2007-05-24 US US11/753,514 patent/US8067436B2/en active Active
- 2007-05-24 US US11/753,503 patent/US8476298B2/en not_active Expired - Fee Related
-
2009
- 2009-02-26 US US12/393,806 patent/US7579473B2/en active Active
-
2010
- 2010-07-12 JP JP2010158337A patent/JP5325173B2/en not_active Expired - Fee Related
- 2010-07-12 JP JP2010158336A patent/JP5185332B2/en not_active Expired - Fee Related
- 2010-07-12 JP JP2010158334A patent/JP5325172B2/en active Active
- 2010-07-12 JP JP2010158335A patent/JP5185331B2/en active Active
- 2010-07-27 AU AU2010204461A patent/AU2010204461B2/en active Active
- 2010-07-27 AU AU2010204459A patent/AU2010204459B2/en not_active Ceased
- 2010-08-27 HK HK10108175.8A patent/HK1141799A1/en unknown
- 2010-10-06 HK HK10109531.5A patent/HK1143068A1/en not_active IP Right Cessation
- 2010-10-25 US US12/911,442 patent/US20110077233A1/en not_active Abandoned
- 2010-11-16 JP JP2010256317A patent/JP2011042686A/en not_active Withdrawn
-
2011
- 2011-09-30 US US13/249,815 patent/US8497284B2/en active Active
- 2011-10-05 HR HR20110707T patent/HRP20110707T1/en unknown
- 2011-10-19 CY CY20111100990T patent/CY1111956T1/en unknown
- 2011-11-02 HR HR20110810T patent/HRP20110810T1/en unknown
- 2011-11-14 CY CY20111101096T patent/CY1112056T1/en unknown
-
2012
- 2012-03-22 US US13/427,093 patent/US20120184523A1/en not_active Abandoned
- 2012-05-22 HK HK12105022.7A patent/HK1164312A1/en not_active IP Right Cessation
- 2012-05-22 HK HK12105023.6A patent/HK1164313A1/en unknown
-
2013
- 2013-05-07 US US13/888,592 patent/US20140155378A9/en not_active Abandoned
- 2013-06-27 US US13/928,977 patent/US20140155396A1/en not_active Abandoned
- 2013-12-26 JP JP2013268453A patent/JP2014074059A/en not_active Ceased
- 2013-12-26 JP JP2013268454A patent/JP5694501B2/en active Active
- 2013-12-26 JP JP2013268455A patent/JP2014055191A/en active Pending
-
2014
- 2014-01-07 HR HRP20140012TT patent/HRP20140012T1/en unknown
- 2014-06-13 HR HRP20140563TT patent/HRP20140563T1/en unknown
- 2014-07-25 LU LU92508C patent/LU92508I2/en unknown
- 2014-07-31 NL NL300678C patent/NL300678I2/nl unknown
- 2014-09-03 CY CY2014037C patent/CY2014037I2/en unknown
- 2014-09-10 BE BE2014C055C patent/BE2014C055I2/fr unknown
- 2014-09-16 HU HUS1400052C patent/HUS1400052I1/en unknown
-
2015
- 2015-04-22 JP JP2015087327A patent/JP2015131859A/en not_active Withdrawn
- 2015-09-08 US US14/847,801 patent/US20150376133A1/en not_active Abandoned
-
2016
- 2016-03-10 US US15/066,872 patent/US20160185725A1/en not_active Abandoned
-
2017
- 2017-06-23 JP JP2017123131A patent/JP2017160270A/en not_active Withdrawn
- 2017-08-28 US US15/688,310 patent/US11124482B2/en active Active
-
2018
- 2018-12-04 HK HK18115513.6A patent/HK1256476A1/en unknown
-
2019
- 2019-01-10 JP JP2019002497A patent/JP2019070015A/en not_active Withdrawn
-
2020
- 2020-07-06 US US16/921,542 patent/US20200331860A1/en not_active Abandoned
- 2020-12-18 JP JP2020209919A patent/JP2021050233A/en active Pending
-
2023
- 2023-11-29 JP JP2023201921A patent/JP2024023447A/en active Pending